Skip to main content
. 2021 Dec 7;9(12):e003783. doi: 10.1136/jitc-2021-003783

Table 1.

Clinical and lab evolution across lines of treatment

Diagnosis (September 2014) First relapse (October 2017) Second relapse (December 2019)
BCMA–CART ARI0002h
(screening)
+1 month ARI0002h +6 months ARI0002h +12 months ARI0002h
CRAB (other symptoms) Present (anemia, bone disease) Present (anemia) Absent, bilateral lower extremity edema
Serum M-protein (g/L) 59.7 0 0 17.6 20.7 4.7 0 0
Serum lambda FLC
(5.71–26.3 mg/L)
1070 7 7 93 231 <0.05 <0.05 14
Proteinuria
Urine M-protein (mg/24 hours)
2043
1052
268
0
144
0
94
0
2626
307
1777
0
1185
0
797
0
Creatinine (<1.3 mg/dL)
eGFR (>60 mL/min/1.73 m2)
0.81
75
0.52
>90
0.55
>90
0.67
>90
0.60
>90
0.67
>90
0.81
75
0.91
66
NT-proBNP (<125 pg/mL)
Troponine I (<45.2 ng/L)
ND
ND
ND
ND
ND
ND
ND
ND
211
7.2
ND
ND
250
8.6
ND
ND
Serum and urine immunofixation IgA lambda
IgA lambda
IgA lambda
Negative
IgG kappa
Negative
IgA lambda
IgA lambda
IgA lambda
IgA lambda
IgA lambda
IgA lambda
Negative
Negative
IgG kappa
Kappa FLC
Plasma cells (%) in bone marrow aspiration before treatment 82
Abnormal phenotype
1
Negative MRD
1
Negative
MRD
25
Abnormal phenotype
23
Abnormal phenotype
0
Negative MRD
0
Negative MRD
1
Negative MRD
Treatment Induction
VRD ×6
ASCT Consolidation VRD ×2+maintenance
I-Rd (CT) ×19
D-Kd x14, since February 2019 D alone. BCMA–CART ARI0002h
Best response (IMWG criteria) after treatment VGPR VGPR
(at 3 months)
sCR VGPR N/A PR sCR sCR

CRAB includes multiple myeloma-related symptoms.

ASCT, autologous stem cell transplantation; BCMA, B-cell maturation antigen; CRAB, hypercalcemia, renal failure, anemia and bone fracture; CT, clinical trial; D, daratumumab; eGFR, estimated glomerular filtration rate; I, ixazomib; IMWG, International Myeloma Working Group; K, carfilzomib; MRD, minimal residual disease; N/A, not applicable; ND, data not available; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PR, partial response; sCR, stringent complete response; VGPR, very good partial response; VRD, bortezomib, lenalidomide and dexamethasone.